Navigation Links
Bionovo Announces 2009 Highlights and Year-End Financial Results
Date:3/15/2010

814) ======= ======= ======== ======== ======== Basic and diluted net loss per common share $(0.04) $(0.05) $(0.20) $(0.22) $(1.18) ====== ====== ====== ====== ====== Shares used in computing basic and diluted net loss per share 105,501 76,363 83,623 76,353 47,345 ======= ====== ====== ====== ======
    
    
                                 Bionovo, Inc.
                          (A Development Stage Company) 
                           Consolidated Balance Sheets
    
                                                            December 31,
                                                            ------------
                                                         2009            2008
                                                         ----            ----
                                                      (unaudited)     (Note *)
                                                            (in thousands)
                                      ASSETS
    Current assets:
        Cash and cash equivalents                        $2,799        $3,270
        Short-term investments                           13,135        10,292
        Receivables                                         251           126
        Prepaid expenses                                    214           334
        Other current assets                                161           471
                                                            ---           ---
              Total current assets                       16,560        14,493
    Property and equipment, net                           6,197         6,938
    Patent pending, net                                     822           575
    Other assets                                            570           498
       
'/>"/>
SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
2. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
4. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
5. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
6. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
7. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
9. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Sclerosis Drugs Market 2014-2018" report to their offering. ... medical condition that results in demyelination, axonal transection, and ... abnormal response by the immune system, which targets neurons ... potentially debilitating disease in which the damage of the ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... to whole range ... of Phase II, III and IV Clinical Trials, ... in off-the-shelf and custom supply chain software for the,biopharmaceutical, ... its tcVisualize(TM) 3.0 clinical trial supply simulator. The,latest generation ...
... the,European Society of Cardiology Congress 2007 (ESC Congress 2007) ... clinical benefits compared to a bare metal stent in ... no differences in safety. At five-year follow-up, the ... to be significantly less likely than the patients in ...
Cached Medicine Technology:Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things ... Alzheimer’s Disease, Dementia, and Memory Loss . , Country singer ... diagnosed with the Alzheimer’s, inspired Seniors Guide writers to review ... The movie, out on October 14, 2014, shows a glimpse ... the disease – which inspires a final tour from the ...
(Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... in five patients operated on for broken bones or other ... new study finds. Less-educated patients and patients who ... to be "doctor shoppers," said study lead author Dr. Brent ... he said, the study suggests that doctors aren,t talking to ...
(Date:8/30/2014)... medication commonly used to treat gout, before and ... potential complications from this type of surgery, but ... effects, according to a study published by ... online to coincide with its presentation at the ... after cardiac surgery include postpericardiotomy syndrome (the occurrence ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's #1 ... Day discount on all SEO services. While working with ... related to internet marketing. Their dedicated team of professionals ... have a deep understanding for their specialization. This further ... since the inception, they have worked with over 5000 ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
Breaking Medicine News(10 mins):Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... is a breach of trust if the court orders to release ... doctor and a patient.// The hospital said that it would do ... who had an abortion at 32 weeks' pregnancy. She plans to ... of Appeal ordered that the woman's files be released to the ...
... OnlySuccess Learning Technologies, a training company based in Chennai, ... children in Dubai and Sharjah. // ... adults with flagship programmes 'Born to Win' and 'Superbkids/Superbteens', ... performances. ,The company currently enjoys a ...
... (IIT) Delhi has developed a high-tech stick to make walking ... // ,Called "smart cane", the stick will help ... inside a room without knocking into things and take a ... technology has been developed by students of the computer science ...
... published on bmj.com in February, that found that the number ... concern among doctors. // They stated that there has been ... that this was true even among low risk women aged ... ,The study also showed that this was probably ...
... Hypnotherapy can be used to relieve pain such as chest ... study researchers randomly divided 28 patients with the condition into ... of hypnotherapy over 17 weeks while the other group ... , ,According to the BMJ, the researchers found that ...
... Association of Clinical Endocrinologists (AACE) Fifteenth Annual Meeting and ... Chicago between April 26-30 will discuss important benefits //of ... deficiency. ,Vitamin D has been ... to heart disease has been attributed to it. Recent ...
Cached Medicine News:Health News:Bad Publicity for the Hospital With Respect To Dwarfism Abortion Case 2Health News:Hi-tech Walking Stick Developed For Visually Impaired 2Health News:Concern Over The Rise In Preterm Deliveries 2
... These award-winning surgical loupes from SheerVision ... users - high resolution optics combined with ... "xx" Ultra-Light loupes weight as little as ... titanium frame, and are available in either ...
... SheerVision manufactures its signature line of ... Sport Frame. These next generation loupes ... ultra-lightweight design, and are multi-coated lens for ... the SV Sport frame offers a stylish, ...
... now the first manufacturer to offer ... the wearer. These next generation loupes ... an ultra-lightweight design, and are multi-coated ... resistance. With SheerVision's proprietary SureFit system ...
... now the first manufacturer to offer ... the wearer. These next generation loupes ... an ultra-lightweight design, and are multi-coated ... resistance. With SheerVision's proprietary SureFit system ...
Medicine Products: